VX-950-TiDP24-C136 - A Trial to Evaluate the Effect of Telaprevir (TVR) on the Results of Electrocardiograms (Electric Recording of the Heart) in Healthy Volunteers
NCT00973388 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 44
Last updated 2010-12-17
Summary
The purpose of this study is to evaluate the effect of telaprevir on the results of electrocardiograms in healthy volunteers. An electrocardiogram is an electric recording of the heart. Telaprevir is being investigated for the treatment of chronic hepatitis C virus infection.
Conditions
- Hepatitis C
Interventions
- DRUG
-
Telaprevir; Moxifloxacin; Placebo
Sponsors & Collaborators
-
Vertex Pharmaceuticals Incorporated
collaborator INDUSTRY -
Tibotec BVBA
lead INDUSTRY
Principal Investigators
-
Tibotec-Virco Virology BVBA Clinical Trial · Tibotec BVBA
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-10-31
- Primary Completion
- 2010-01-31
- Completion
- 2010-01-31
More Related Trials
-
A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ribavirin) in Subjects With Chronic Hepatitis C With Compensated Cirrhosis
NCT01516918 ·Status: COMPLETED ·Phase: PHASE2
-
VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir.
NCT00903773 ·Status: COMPLETED ·Phase: PHASE1
-
An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection
NCT00580801 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection
NCT01080222 ·Status: TERMINATED ·Phase: PHASE2
-
Telaprevir in Genotype 3 HCV
NCT02087111 ·Status: COMPLETED ·Phase: PHASE4
-
VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo
NCT01054573 ·Status: COMPLETED ·Phase: PHASE3
-
An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants
NCT00528528 ·Status: COMPLETED ·Phase: PHASE2
-
A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment
NCT00703118 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects
NCT01511432 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 2a Study to Evaluate Viral Kinetics and Safety of Telaprevir in Participants With Genotype 2 or 3 Hepatitis C Infection
NCT00561015 ·Status: COMPLETED ·Phase: PHASE2
-
Study of VX-985 in Subjects With Chronic Hepatitis C
NCT01144936 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV
NCT00983853 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study of VX-950, Pegasys®, and Copegus® in Hepatitis C
NCT00336479 ·Status: COMPLETED ·Phase: PHASE2
-
Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®)
NCT03002818 ·Status: COMPLETED
-
Open-Label Safety Study of Telaprevir and Sofosbuvir in Chronic Hepatitis C Genotype 1
NCT01994486 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and PK Study of MP-424 to Treat Chronic Hepatitis C
NCT00591214 ·Status: COMPLETED ·Phase: PHASE1
-
An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus
NCT01701063 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study to Examine Multiple Doses of TMC647055 in Combination With Telaprevir
NCT01582035 ·Status: COMPLETED ·Phase: PHASE1
-
TMC435350-TiDP16-C101 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing
NCT00938899 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response
NCT00758043 ·Status: COMPLETED ·Phase: PHASE3
-
A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy
NCT00535847 ·Status: COMPLETED ·Phase: PHASE2
-
Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers
NCT01766115 ·Status: WITHDRAWN ·Phase: PHASE4
-
Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B
NCT03672188 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Telaprevir (VX-950), Pegasys and Copegus in Hepatitis C (PROVE3)
NCT00420784 ·Status: COMPLETED ·Phase: PHASE2
-
VX-950 and Peginterferon for Hepatitis C
NCT00251199 ·Status: COMPLETED ·Phase: PHASE1